Proactive Investors - Finance
11 Jul 2026, 10:38 UTC · 2h ago
Futura Medical: US Eroxon deal and WSD4000 breakthrough - ICYMI
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
Proactive Investors - Finance
11 Jul 2026, 10:38 UTC · 2h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
What the story claims
4 claims · each scored for market impact
Futura Medical's WSD4000 candidate showed statistically significant improvement over placebo in a study for female sexual dysfunction, de-risking the upcoming Phase 3 trial. — Positive clinical data for a novel OTC treatment significantly increases the probability of regulatory approval and future revenue streams.
+0.70Futura Medical has partnered with Market Performance Group (MPG) to manage the US commercial execution and distribution of Eroxon. — Transitioning to a more actively managed commercial strategy with an experienced partner improves the likelihood of scaling US sales.
+0.50Eroxon is currently generating approximately $5 million in trade-level sales. — Provides a concrete baseline of commercial traction and proof-of-concept for the product's market viability.
+0.40Continue reading
6 related stories
Top 3 movers · tap to explore
Futura Medical targets a potential launch of WSD4000 in the US and Europe by early 2028, pending Phase 3 completion and funding. — Establishes a clear timeline for new product commercialization, though it remains subject to funding and trial success.
+0.30Which stocks this story touches
The company announced a strategic US commercial partnership and reported positive clinical data for its WSD4000 product candidate.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
MarketBeat
13h ago
